Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.

Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its ...

Please provide your email address to receive an email when new articles are posted on . Harrow will inherit MELT-300, a sublingually delivered sedation product. The company plans to submit a new drug ...

Constance Grady is a senior correspondent on the Culture team for Vox, where since 2016 she has covered books, publishing, gender, celebrity analysis, and theater. I couldn’t tell that there was ...

Eyecare pharmaceutical company Harrow Health is expanding its Nashville corporate headquarters in a $3 million investment that is slated to bring 147 new jobs to the city. Harrow announced the move ...

Harrow, Inc. recently reported third-quarter 2025 results, highlighting a revenue increase to US$71.64 million and a move from a net loss to a net profit compared to the same period last year. The ...

It is one of the world’s oldest running annual sporting fixtures which, over the years, has featured a British Prime Minister, international cricketers and the Romantic poet Lord Byron. For more than ...